WO2001021199B1 - Vaccin a adn cible sur les cellules dendritiques a efficacite elevee - Google Patents

Vaccin a adn cible sur les cellules dendritiques a efficacite elevee

Info

Publication number
WO2001021199B1
WO2001021199B1 PCT/EP2000/009305 EP0009305W WO0121199B1 WO 2001021199 B1 WO2001021199 B1 WO 2001021199B1 EP 0009305 W EP0009305 W EP 0009305W WO 0121199 B1 WO0121199 B1 WO 0121199B1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
nucleic acid
sequence
antigen
acid molecule
Prior art date
Application number
PCT/EP2000/009305
Other languages
English (en)
Other versions
WO2001021199A1 (fr
Inventor
Thomas Brocker
Original Assignee
Thomas Brocker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Brocker filed Critical Thomas Brocker
Priority to CA002404709A priority Critical patent/CA2404709A1/fr
Priority to AU77810/00A priority patent/AU7781000A/en
Priority to EP00967758A priority patent/EP1221967A1/fr
Publication of WO2001021199A1 publication Critical patent/WO2001021199A1/fr
Publication of WO2001021199B1 publication Critical patent/WO2001021199B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un vaccin contenant une molécule d'acide nucléique comprenant: (a) un promoteur spécifiquement actif dans les cellules présentatrices d'antigène; et, fonctionnellement reliée au promoteur précité, (b) une séquence nucléotidique codant un antigène. L'invention se rapporte également à un procédé de vaccination d'un mammifère selon lequel on administre à un mammifère une dose adéquate du vaccin de l'invention.
PCT/EP2000/009305 1999-09-23 2000-09-22 Vaccin a adn cible sur les cellules dendritiques a efficacite elevee WO2001021199A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002404709A CA2404709A1 (fr) 1999-09-23 2000-09-22 Vaccin a adn cible sur les cellules dendritiques a efficacite elevee
AU77810/00A AU7781000A (en) 1999-09-23 2000-09-22 Highly efficient dendritic cell-targeted dna-vaccination
EP00967758A EP1221967A1 (fr) 1999-09-23 2000-09-22 Vaccin a adn cible sur les cellules dendritiques a efficacite elevee

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99118809.5 1999-09-23
EP99118809 1999-09-23
EP00111993.2 2000-06-20
EP00111993 2000-06-20

Publications (2)

Publication Number Publication Date
WO2001021199A1 WO2001021199A1 (fr) 2001-03-29
WO2001021199B1 true WO2001021199B1 (fr) 2001-10-18

Family

ID=26071023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009305 WO2001021199A1 (fr) 1999-09-23 2000-09-22 Vaccin a adn cible sur les cellules dendritiques a efficacite elevee

Country Status (4)

Country Link
EP (1) EP1221967A1 (fr)
AU (1) AU7781000A (fr)
CA (1) CA2404709A1 (fr)
WO (1) WO2001021199A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226717D0 (en) * 2002-11-15 2002-12-24 Collen Res Foundation D DNA vaccination
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
WO1999030734A1 (fr) * 1997-12-18 1999-06-24 G.D. Searle & Co. Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer

Also Published As

Publication number Publication date
EP1221967A1 (fr) 2002-07-17
WO2001021199A1 (fr) 2001-03-29
AU7781000A (en) 2001-04-24
CA2404709A1 (fr) 2001-03-29

Similar Documents

Publication Publication Date Title
JP6655626B2 (ja) 新規な免疫原性ペプチド
DE69735376T2 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
US7528224B1 (en) Peptide for triggering an immune reaction against tumor cells
AU2022203627A1 (en) Novel Immunogenic CD1d Binding Peptides
JP2003502283A5 (fr)
NZ583028A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2000034317A3 (fr) Modification de l'immunogenicite de proteines
EA003832B1 (ru) Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
CA2293489A1 (fr) Inhibiteurs de l'activite de sequences immunostimulatrices de l'adn
CA2290485A1 (fr) Procede de production de proteines non immunogenes
WO1996011279A3 (fr) Reponse immunitaire amelioree par l'introduction par recombinaison du gene de la cytokine et/ou du gene de la proteine co-stimulatrice b7 dans un systeme d'expression virale
WO1996010419A3 (fr) Composition comprenant un virus de recombinaison exprimant un antigene et un virus de recombinaison exprimant une molecule immunostimulatrice
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
JPH08502244A (ja) 免疫調節ペプチド
WO2003039225A3 (fr) Ensemble ordonne d'antigenes destines au traitement de maladies osseuses
JP4033497B2 (ja) ワクチン製剤
EP1035780B1 (fr) Procede servant a purifier des complexes de peptides et de proteines du stress
WO2000025722A3 (fr) Vaccins ameliores
US7862828B2 (en) Allergy vaccines containing hybrid polypeptides
WO2001021199B1 (fr) Vaccin a adn cible sur les cellules dendritiques a efficacite elevee
AU5573196A (en) A pluripotent vaccine against enveloped viruses
Weiss et al. Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response
WO2003033660A3 (fr) 9136, membre humain de la famille des aldehyde deshydrogenases et applications
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2000967758

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000967758

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2404709

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: JP